Type 1 Diabetes Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors IntroductionOverview Intensive Therapy Reduces Diabetes Complications Rates Variability in TimeAction Profile of Basal Insulins ID: 769970
Download Presentation The PPT/PDF document "Type 1 Diabetes: Expanding Options for A..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors
Introduction/Overview
Intensive Therapy Reduces Diabetes Complications Rates
Variability in Time-Action Profile of Basal Insulins*
Intensive Insulin Therapy Is Limited by Hypoglycemia and Weight Gain
Rates of Glycemic Control in T1DM by Age Group
HbA1c Testing and Time-in-Range Outcome
Purpose of Adjunct Therapies in T1DM
Adjunct Therapies: Metformin
Pramlintide Meta-Analysis in T1DM: Adverse Events
ADJUNCT One Liraglutide + Insulin: Effect on HbA1c
T2DM Therapies for T1DM: SGLT Inhibitors
SGLT1/2 Inhibition
InTANDEM 2: Sotagliflozin in T1DM
Dapagliflozin DEPICT-1 and DEPICT-2: Study Design
DEPICT-1: Change in HbA1c Over 24 Weeks
DEPICT-2: Adjusted Mean Change in HbA1c
DEPICT-2: Time in Target Range
The EASE Clinical Development Program
EASE Trial: Efficacy Results
SGLT2 Inhibitors: Kidney Damage, Genital Infections, and Other AEs
Forest Plot: Events Suggestive of Genital Infections in Patients With T2DM Receiving SGLT2 Inhibitors
Safety Issues: EASE, InTANDEM
DKA Risk With SGLT2 Inhibitors
Managing the DKA Risk
Managing the DKA Risk (cont)
Managing the DKA Risk (cont)
STICH Protocol
Summary and Conclusions
Abbreviations
Abbreviations (cont)